BioSpace News Archive

Barbara Bodem to Succeed Steven J. Strobel as CFO

Cannabis leader has completed four federally legal shipments of cannabis to the United States to pursue advanced R&D work with Battelle

- Further strengthens patent portfolio

Accula RSV Test FDA Cleared for Both Children and Adults

Marker Therapeutics, Inc. today announced the appointment of Anthony H. Kim as its new Chief Financial Officer. Michael J. Loiacono, who has served as the Company’s Chief Financial Officer and Chief Accounting Officer since August 2016, will continue in his role as Marker’s Chief Accounting Officer.

Acceleron Pharma Inc. today announced it will host a conference call and live audio webcast on Monday, December 3, 2018 at 9:00 a.m. EST to review the MEDALIST and BELIEVE Phase 3 trial presentations of luspatercept at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition taking place on December 1-4, 2018 in San Diego, California.

- Global Trial of RP-L102 Utilizing No Conditioning and “Process B” On Track for Early 2019 -

International Expansion Extends to 21 Countries

- Third Rock Ventures LLC today announced Reid Huber, Ph.D., is joining the firm as a partner.

Celgene Corporation and bluebird bio, Inc. today announced the completion of enrollment for the KarMMa pivotal study of bb2121, the companies’ lead investigational anti-BCMA CAR T cell therapy candidate for patients with relapsed and refractory multiple myeloma. bb2121 is being developed as part of a Co-Development, Co-Promote and Profit Share Agreement between Celgene and bluebird bio.